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ABSTRACT 
 
PILOT STUDY: PROGRAM EVALUATION OF 
PEANUT ORAL IMMUNOTHERAPY 
IN A PRIVATE CLINIC 
 
The privilege of providing a therapy perceived by patients and families as “life changing” 
has seasoned physicians describing food oral immunotherapy (OIT) as one of “the most 
impactful and rewarding thing that they have done in medicine” (Wasserman, Jones, & Windom, 
2018).  OIT is a medical treatment that allows the immune system to become desensitized to a 
food to which it may otherwise be allergic.  This is not a cure for food allergies but a way to 
decrease the incidence of anaphylaxis due to accidental ingestion. Living with food allergies can 
be distressing due to the daily fear of exposures. The decreased quality of life for food allergic 
children and their families has prompted numerous OIT research projects over the past two 
decades. This evidence-based research is now being used in OIT treatment programs within 
hospitals and private practice allergy clinics.  A pilot study program evaluation was completed 
for a newly implemented OIT program within a private allergy clinic. The focus of this study 
was two-fold: First, it shows how private practice OIT success and safety statistics compare to 
those reported from academic medical centers;  Second, it examines parental anxiety and 
elements found helpful during their child’s OIT process. Finally, useful information will be 
offered for OIT implementation within private practices during the program evaluation 
recommendations section.  
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CHAPTER 1: INTRODUCTION 
Food allergy awareness has become such a public health concern that Healthy People 
2020 created goals to aid in the reduction of food allergy-related anaphylaxis 
(HealthyPeople.gov).  Food allergies affect 8% of children in the United States (U.S.), and 
account for 53,700 episodes of anaphylaxis, 125,000 emergency department visits, and 150 
deaths each year in the United States (Gupta et al., 2011).  People with peanut or tree-nut 
allergies account for 80% of these anaphylactic reactions and only 20% of children will outgrow 
them (Broome, et al, 2015).  Stress on the child and parents of children with peanut allergies may 
be overwhelming due to the daily threat of accidental ingestions. Peanut allergy research has 
developed promising new technologies over the past decade and according to Wasserman, et al., 
“with appropriate planning and precautions, peanut oral immunotherapy can be performed in an 
allergy office” (2019).  Most recently, two biopharmaceutical companies (Aimmune 
Pharmaceuticals and Viaskin Peanut Technologies) have received Fast Track and Breakthrough 
Therapy designation from the US Food and Drug Administration (FDA), promising approved 
peanut desensitization therapy products commercially available as early as 2019, (Tilles, S. & 
Petroni, D., 2018). Once these therapies receive FDA approval, healthcare providers and 
institutions will be considering implementation; however, proper planning is warranted before 
starting any new program. This paper will highlight key elements of a peanut OIT program via 
program evaluation, and with input from parents of children that have experienced the OIT 
process.   
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The Problem 
Numerous peer-reviewed publications have discussed various peanut OIT study 
protocols, maintenance dosing, safety concerns, as well as the overwhelming evidence that 
peanut OIT improves quality of life for the recipients and their families (Panjo, et al., 2017; Bird, 
et al., 2018; Wasserman, et al, 2014 and 2019; Bégin, Chinthrahah, & Nadeau, 2014). Since OIT 
implementation in private practice is still considered to be in its pioneering stages, a program 
evaluation documenting specific outcomes of such a program offers insight for all allergists. It is 
imperative that clinicians considering this therapy for their own patients understand that food 
allergies and anxiety go hand in hand. Currently there are no published studies discussing how to 
decrease parental anxiety during OIT therapy, nor any discussions about what elements of a 
program are viewed as most valuable by parents themselves. Surveying parents about the 
specific anxiety-reducing facets of a program was determined to be a valuable outcome measure 
by the OIT providers of this private clinic and was measured as part of this program evaluation.  
Purpose 
 A private allergy clinic recently implemented a pilot program for peanut OIT and a year 
later has undergone program evaluation to identify process improvement needs before expanding 
to satellite locations. The CDC’s Appendix F form was used as a template for the program 
evaluation, and for the purpose of this paper the following components will be reported:  
- Effectiveness of therapy (measured by the number of patients reaching maintenance 
dose)  
- Safety concerns related to adverse reactions during OIT (measured by total number of 
adverse reactions during escalation phase)  
- Cost effectiveness  
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- Parent perception of anxiety reducing elements of OIT program (as reported by survey) 
- Positive and negative impact of OIT program on the practice (impact on resources such 
as available staff, peanut free locations in clinic, parent satisfaction of program) 
 Assumptions underlying this program evaluation are those by careful evaluation of the 
above noted elements, successful activities and process improvement opportunities can be 
addressed. This is considered relevant due to the lack of published information related to OIT 
program implementation. 
Background 
 Peanut allergies affect 1 in 70 children in the United States (US), and are considered one 
of the most prevalent food allergies (Bird et al., 2018), and are responsible for over half of all 
food–related anaphylactic deaths in the US (Wood, 2017). Peanut allergies most commonly 
begin in childhood, and 80% do not outgrow it (FARE, 2018), As many as 50% of peanut 
allergic individuals have reported accidental ingestion over a 2-year period, portraying how 
minimal exposures can cause life-threatening reactions, as is the case with cross-contaminated 
foods (Bird, et al., 2018). Theories surrounding peanut allergy development are not clear since 
no studies have been able to pinpoint a precise cause. The hygiene hypothesis states too little 
exposure to bacteria and viruses weakens the immune system, versus the dietary hypothesis 
which states a broader exposure to various foods help strengthen the immune system (Rance & 
Goldberg, 2013). For decades pediatricians recommended infants avoid allergenic foods such as 
peanuts, and new research finds that this may have contributed to the recent rise of peanut 
allergies (Immune Tolerance Network, 2019). The new 2010 Guidelines for the Diagnosis and 
Management of Food Allery in the United States was impacted by the LEAP (Learning Early 
about Peanut Allergy) studies and now recommends early introduction of peanuts to infants 
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(based on varying risk levels which would be determined by a physician) in order to stimulate a 
protective immune response (McCarthy, 2019).  
Since there is no cure for peanut allergies, current evidence based practice guidelines 
direct health care providers to educate patients (and families) with peanut allergies to avoid this 
allergen, and to carry epinephrine injectables at all times since accidental peanut ingestion can be 
fatal for these individuals (FARE, 2018).  Treating food allergies has become a highly debated 
topic in the world of immunology, with experts in the field discussing the merits and downfalls 
of food allergy immunotherapy (AAAAI, 2019). Potential therapies (not cures) for peanut 
allergies are being developed by pharmaceutical companies and expect FDA approval soon 
(Tilles, S. & Petroni, D., 2018). These new therapies are being considered by allergists for 
implementation into their own practices (Greenhawt & Vickery, 2015).   
Physical effects of Food Allergies  
When a person ingests a food to which they are allergic, a variety of allergic reactions 
can occur, ranging from a simple skin rash to life-threatening anaphylaxis. These reactions occur 
because histamines are released by mast cells located in the skin, gut, lungs, mucosa, and around 
blood vessels. Symptoms vary and can be unpredictable, ranging from mild discomforts such as 
skin rash, urticaria, rhinitis, or mild abdominal pain to more moderate symptoms such as nausea, 
vomiting, angioedema, and wheezing. Anaphylaxis is the most severe symptom that can occur 
during an accidental ingestion of a food allergen, causing respiratory distress, throat swelling, or 
circulatory collapse with extreme hypotension.  
Psychosocial Consequences of Food Allergies  
The daily threat of anaphylaxis causes much anxiety for food allergic (FA) children and 
caregivers (Broome et al., 2015), and for many it defines their lifestyle.  Parents are under the 
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daily threat of their child potentially having a life-threatening reaction each time they eat. The 
anxiety that develops from this fear can also lead to overprotective behaviors by restricting a 
child’s diet, playdates, social events, and travel; children may also develop learned behaviors 
such as helplessness when parents control every aspect of their child’s life (Quach & John, 
2018).  A third of FA children report being bullied for their food allergies, (Peck & Larson, 
2018), and according to Polk & Dinakar (2017), peanut allergic children experience greater 
anxiety when eating at social events than children with insulin-dependent diabetes. These and 
other similar experiences significantly affect quality of life in children and caregivers.  
An alternative therapy for treating food allergies is oral immunotherapy (Panjo, et al., 
2017). As this treatment becomes more available to healthcare institutions, managing FA anxiety 
may become a key element of any OIT program, as evidenced by a study focusing on the QOL 
of these patients and their families before, during, and after OIT, published by Epstien-Rigbi, et 
al., (2019). The authors report that quality of life (QOL) temporarily decreases during the 
process of OIT for some families, but improves significantly once maintenance dosing (or even 
partial desensitization) is achieved. This temporary decrease in QOL is most likely due to the 
fact that the first half of OIT encompasses challenges such as fear of reactions and general 
anxiety about the program. This temporary decrease of QOL during OIT therapy warrants further 
discussion, including how to minimize anxiety during therapy.  
Investigating Lerwick’s four treatment principles for minimizing anxiety during 
healthcare visits and therapies - choices, agenda, resilience, emotional support (CARE) - may 
provide useful information (2015). When choices are offered during OIT therapy, such as the 
vehicle the patient would like to use to mix the peanut powder in (applesauce or pudding), the 
patient feels a sense of empowerment by choice. When providers offer an agenda to the patient 
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and family, the healthcare experience becomes clear from the start reducing fear of the unknown, 
and can be easily provided during orientation meetings with families and patients, as well as 
throughout the course of the therapy. Resilience can be discovered by asking parents to describe 
how they have managed their child’s peanut allergy, and what they would like to do differently. 
Fear is a common emotion for patients and parents of OIT therapy, especially with previous 
anaphylactic experiences from accidental exposures. Emotional support can be provided by 
discussing these emotions prior to and during therapy as reported by Lerwick (2016), as would 
offering availability of an OIT provider during therapy (i.e., by phone or electronic mail). 
How OIT Works  
In the past decade research trials have been conducted in large academic institutions 
introducing oral desensitization to the most common food allergies with great success (FARE, 
2018).  It is important to note that oral immunotherapy is considered a desensitization program 
and not a cure, as long-term unresponsiveness continues to be researched and is unknown to 
date. The immunologic change during oral immunotherapy is described by Wood (2017) as a 
process that increases food–specific IgG4 while basophil and mast cell responsiveness decreases.  
The process of peanut OIT has three stages; first is the initial escalation, followed by a series of 
“up dosing” appointments which slowly increase the patient’s reactivity threshold, until a target 
maintenance dose is achieved. The final phase is considered the maintenance phase where the 
patient must continue daily dosing in order to maintain tolerance. Since there is no ideal 
protocol, numerous studies publish a variety of approaches on how to conduct the three phases, 
including dosing recommendations and maintenance dosing (Panjo, et al., 2017; Bird, et al., 
2018; Wasserman, et al, 2014 and 2019; Bégin, Chinthrahah, & Nadeau, 2014). This pilot study 
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for which the program evaluation is being conducted chose a protocol that would be achievable 
in approximately six months.  
Burdens To Enrolling In OIT  
 Despite reported adverse reactions being common in OIT (mild skin or mouth itching, or 
abdominal discomfort), the ability to receive this therapy has become very desirable by many 
parents since the margin of safety for FA individuals is greatly improved, and safety is an 
essential concept for patients, parents, and clinicians (Shreffler et al., 2019). Since no 
pharmaceutical product is yet commercially available, private clinics that are pioneering OIT 
programs are hiring their own pharmacists and pharmacy technicians to carefully measure peanut 
protein powder into appropriate doses (using a commercially manufactured powder). Once FDA 
approval allows for a premeasured peanut powder to be prescribed, more independent allergy 
clinics will consider offering this therapy to patients in their communities (Greenhawt & 
Vickery, 2015).  
While OIT therapy is considered a long-term commitment lasting years, since tolerance is 
still under investigation, at this time it appears that in most patients desensitization can be lost if 
dosing is discontinued (Wood, 2017). How long the “long term commitment” lasts continues to 
be analyzed with ongoing longitudinal studies (Wasserman et al., 2019). Fortunately there are a 
number of peanut products with calculatable protein measurements that Wasserman, et al., has 
published (2019), allowing for a variety of dosing options when one peanut product becomes less 
palatable then another (i.e. specific peanut containing candies, and powders that are 
commercially available).  
Parents report that undergoing OIT with their children causes much anxiety, especially 
when they are asking their peanut allergic child to eat the very food that can cause great harm 
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(Epstien-Rigbi, et al., 2019 ). Because it can be so anxiety-provoking, establishing trust between 
the parents, patients, and providers is crucial, as is for the provider to disclose potentially 
harmful effects of OIT even during the maintenance phase, such as eosinophilic esophagitis, and 
the continued threat of anaphylaxis if accidental ingestion of peanut is more than the individual’s 
threshold tolerance. These discussions should take place when recommending OIT as an option, 
but discussed in more detail while obtaining consent for treatment.  
Benefits to enrolling in OIT  
Shreffler et al., reports that according to FDA Allergenic Products Advisory Committee, 
achieving a level of protection that reduces the rate of or degree of allergic reactions is clinically 
meaningful, and goes on to report that by desensitizing a person to approximately one peanut 
(300 mg), anaphylaxis due to accidental ingestion may be reduced by 95%, thus providing a 
margin of safety for peanut allergic patients encountering trace levels of peanut (2018). This 
amount of safety allows the individuals to ingest products that report “trace amounts of peanut” 
on their labels. As noted earlier, achieving any level of tolerance to peanut that improves safety 
from anaphylaxis due to accidental ingestion increases QOL for the allergic individual as well as 
the family.  
Undergoing OIT and achieving a maintenance level of 300 mg of peanut protein takes 
approximately six months, after which the individuals continue to dose daily at the maintenance 
level of 300 mg. Wesserman et al., has recently reported that Peanut Specific IgE levels 
commonly fall during the first year of maintenance dosing (2019), thus OIT patients may 
anticipate being able to tolerate ingesting higher than maintenance dose levels if challenged 
during an allergist’s office visit (referred to as an oral challenge).   
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Theoretical Framework 
Nursing models of care encourage using evidence-based practice (EBP) to promote high 
quality care. Since both nursing models and EBP promote incorporating evidence into healthcare 
practice decisions, nurse practitioners (NP) are in an excellent position to lead EBP changes in 
healthcare (Dontje, 2007).  The Iowa Model of Evidence Based Practice (EBP) was used to 
guide the implementation of OIT research into the clinical practice at a private allergy clinic. The 
model can be considered a type of holistic approach since it considers the entire healthcare 
system as well as its individual contributors and resources. The Iowa Model, developed by 
Marita G. Titler, is designed to guide clinical practice using a scientific method of evidence-
based research in improved practice, with the ultimate goal of answering clinical questions, and 
predicting patients’ outcomes (Titler et al., 2001). Elements of the IOWA Model are: (1) identify 
a problem, (2) determine a plan, (3) form a team, (4) gather evidence, (5) critique and synthesize 
the evidence, (6) determine the validity and appropriateness of the evidence, (7) pilot change, (8) 
determine if the change is appropriate for practice, (9) implement, and (10) disseminate results. 
Implementation of Theoretical Framework  
The problem identified by this study’s allergy clinic was the growing number of patients 
diagnosed with food allergies, (especially peanut allergies), without available treatment options. 
Providers conducted annual reviews with each family discussing their food allergy action plan, 
reiterating avoidance and how to use an epinephrine injectable for accidental ingestion and 
anaphylaxis as directed by the national guidelines (FDA, 2019). Resolving this problem by 
introducing OIT, which is anticipated to lead to improved QOL for their patients, is a priority for 
the private practice stakeholders, especially since research suggested that OIT can be 
successfully implemented in private allergy clinics (Wasserman et al., 2019, and Tilles & 
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Petroni, 2018). Step 2 of the IOWA model: Implementing a peanut OIT program, was 
determined by the physicians of the group. Step 3 led to the formation of the taskforce which was 
responsible for gathering the evidence (included in step 4), critiquing and synthesizing the 
evidence (step 5) in order to determine validity and appropriateness of the evidence (step 6).  
Guidelines were created with regard to protocols, safety, dosing, maintenance targets, utilizing 
published research (as described earlier), as well as establishing relationships with mentoring 
clinics that have reputable OIT programs. Step 7 of the model was defined as the pilot program 
implementation in May of 2018. Step 8 determines if change is appropriate for practice and 
utilized a template provided by the CDC, Appendix F (2019). This template was originally 
created to evaluate state and individual clinic asthma programs, but was found to be generic 
enough to be used for this peanut OIT program evaluation.  The program evaluation took place 
during the month of February 2019. The program evaluation will determine the successes of the 
OIT program, as well as offer recommendations about quality improvements that may be 
considered. Step 9, or implementation of changes will occur after quality improvement 
recommendations are decided upon by the stakeholders of the clinic. Step 10 will take place in 
the future as the peanut OIT program continues to grow and as commercially available products 
become available. Utilizing the Iowa Model of EBP, and then transitioning to the CDC Program 
Evaluation helped guide the implementation of the new peanut OIT program and ultimately 
assisted with the program evaluation. Both were invaluable tools.  
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CHAPTER 2:  LITERATURE REVIEW 
 Prior to the clinic’s implementation of the peanut OIT program, optimal therapy 
guidelines were addressed and agreed upon by the clinic physicians using the best available 
evidence and expert knowledge. Thus detailed clinical protocols were not reviewed during this 
program evaluation rather, emphasis was placed on measurable outcomes of the OIT program, 
and how the program can be improved. Since outcomes of the program evaluation entail food 
allergy treatment success, safety guidelines surrounding food OIT, the psychosocial aspects of 
living with food allergies and how to address the anxiety involved, the following publications 
were used as guides.  
European Guidelines Publish Evidence-based Recommendations 
 The European Academy of Allergy and Clinical Immunology Task Force on Allergen 
Immunotherapy for IgE-mediated Food Allergy published evidence-based recommendation for 
food allergen immunotherapy (Pajno et al., 2017).  The Appraisal of Guidelines for Research & 
Evaluation (AGREE II) framework was used to design appropriate representation in terms of 
stakeholders, relevant literature, and non-bias recommendations. This guideline is the first of its 
kind assisting clinicians with the management of food allergen immunotherapy, pointing out 
general considerations before initiating therapy, general contraindications, effectiveness of the 
different immunotherapy approaches, safety, and addresses gaps for future research.   
AR101- DBPCFC Clinical Trial 
Efficacy and safety of peanut OIT is reported in great detail in the randomized, double-
blind, placebo-controlled clinical trial conducted by Bird, et al., (2018). The sample size was 55, 
including individuals aged 4 to 26 years, and an up-dosing phase lasting 20-34 weeks. The 
endpoint of this study was defined as the number of subjects successfully ingesting at least 300 
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mg of a pharmaceutically prepared peanut protein compound (AR101) without major dose-
limiting symptoms. Adverse reactions occurred in 95% of the subjects, reporting at least one 
mild to moderate reaction during treatment, with the most common complaint being GI 
symptoms (mild oral pruritis, abdominal pain, or vomiting) reported by 66% of the group 
receiving peanut protein.  
Incidence of Anaphylaxis with OIT 
Creating safety guidelines for a peanut desensitization program is a key component 
addressed in protocol development. Allergic reactions to peanut 
exposures can vary from mild symptoms to severe anaphylaxis. It is valuable for any clinic 
considering peanut OIT to review the literature regarding frequency of symptoms, especially 
severe symptoms warranting epinephrine auto injectors. Wasserman et al., (2014) completed a 
retrospective medical record review of 352 patients that underwent peanut OIT in 5 private clinic 
settings. This review included 79,726 escalation doses, with 57 dose-related reactions (0.7 per 
1,000 doses) warranting epinephrine. All 57 reactions were effectively treated by the epinephrine 
and no hypotension warranting intravenous fluids or symptoms of shock was documented. The 
data analysis from this study suggests that the private clinic setting results are similar to trial 
results from larger institutional OIT studies  (Wasserman at al., 2014), and overall systemic 
reactions warranting epinephrine is comparable with the 0.1% systemic reactions noted with the 
high dose subcutaneous immunotherapy used in what is commonly known as “allergy shots” 
(Wasserman at al., 2014).  The final data points are encouraging, stating 79% of the 352 
participants reached maintenance doses (taking into account attrition).  
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Reducing Parental Anxiety During OIT 
Since research regarding the impact of peanut OIT is still in progress, creating a program 
evaluation that includes important stress-reducing components may aid in future OIT program 
development. Herbert, Shamesh, and Bender’s 2016 clinical management review article about 
food allergy anxiety described how families reported benefit from having their medical provider 
listen to their concerns while discussing food allergies. Behavioral interventions addressing 
parents needs of children with food allergies are few, but are touched upon in this report 
suggesting parent support groups and workshops improving food allergy competence and 
decreased burden. Other valuable findings of this review included parental anxiety and 
psychosocial concerns related to food allergies and parents admitting that they struggled to 
recognize symptoms of mild food allergy symptoms versus anaphylaxis (2016). Findings from 
Herbert et al.’s article (2016) are especially useful during educational protocol development for 
any private clinic OIT program, and was especially helpful during the parental survey creation 
for the program evaluation.  
Another article from Epstein-Rigbi, et al., (2019) focuses on how QOL is affected 
throughout the OIT process. This prospective cohort study utilized the Food Allergy Quality of 
Life Questionnaire-Parent Form (FAQLQ-PF), a validated testing tool developed to examine the 
QOL of children as assessed by their parents. Again, this study’s results report a consistent 
improvement in QOL for these families once the patient reaches maintenance. This article does 
points out however, that additional anxiety is experienced by these families during the OIT 
process itself, concluding that implementing methods to overcome these challenges are 
beneficial for the overall experience.  
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Gap Analysis 
 All of the articles in this literature review served important and specific purposes within 
the peanut OIT pilot study evaluation. Since peanut OIT implementation within the private 
practice setting is relatively new, no published data is available to guide private allergy clinics 
regarding logistics, patient and family education, and reducing parental anxiety during therapy.  
These notable gaps in the literature will be addressed during the discussion of results highlighted 
by the program evaluation.   
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CHAPTER 3: METHODOLOGY 
Design 
 The U.S. Center for Disease Control has a valuable website of resources and materials 
that can be utilized for program evaluations (CDC, 2018). Appendix F is the Individual 
Evaluation Plan Outline that was used for an asthma program evaluation guide, and has been 
used here to evaluate the OIT program. A separate survey was created by the researcher (and 
approved by the physicians of the group, prior to IRB submission) measuring the parent’s 
perception of how specific elements of the OIT program helped reduce parental anxiety during 
their children’s OIT experience.   
 Individuals involved in the program evaluation include stakeholders, identified as the 
board of directors for the private clinic, and individuals that were identified as “OIT champions” 
including practicing physicians, administrators, and healthcare providers (nurses and NPs) 
leading the implementation of the OIT program. Lerwick’s CARE principles were considered 
during the peanut OIT program development so as to include elements in the program that would 
reduce parental anxiety during therapy.  The importance of these elements were then tested by 
incorporating parental input of patients enrolled in the program. This was accomplished by 
having the parents complete a program survey containing ten questions rating anxiety-reducing 
elements of the program and other activities that helped ease anxiety.   
The program evaluation focuses on three themes; (1) effectiveness of therapy (including 
safety evaluation via retrospective data collection), (2) parental anxiety-reducing elements of the 
OIT program (using a parent survey), and (3) the impact of adding an OIT program to a private 
allergy practice, (including cost effectiveness, and impact on resources). The pilot study started 
September 1, 2018 and was completed February 28, 2019, and parental surveys were 
DocuSign Envelope ID: FA0BAE8F-FCA7-4EA1-9BEF-C24143F5C43C
 16 
administered during the second half of their child’s OIT program. The program evaluation took 
place during the month of February 2019. No special procedures were used.  
Potential Benefits 
 Potential benefits of this evaluation includes discovering program elements that may 
require quality improvements, thus allowing stakeholders the opportunity to make practice-
changing decisions. Potential benefits of the parental survey findings will also help the 
stakeholders understand what improvements are necessary for parental satisfaction of the 
program. Findings from this pilot study evaluation will benefit future clinicians as well as 
patients considering OIT programs across the country.  
Potential Risks  
 Potential foreseeable risks are minimal since this project is focusing on the program 
evaluation of the pilot program, rather than the OIT peanut protein powder treatment. Potential 
OIT parental anxiety triggers were addressed within the program via pre-enrollment education 
meetings with the allergist and OIT nurse practitioner, as well as offering referral to a local food 
allergy anxiety specialist. Informational packets given during orientation allow parents to review 
the program with their families before committing to the approximately six-month program. 
Additional food allergy anxiety- reducing measures are included in the parental program survey 
(Appendix A). 
Sample 
 Participant size was small (n=15) since this was a pilot study consisting of parents of 
children undergoing peanut OIT, and was one of convenience taking place at a private allergy 
clinic.  The 15 parents (12 mothers and 3 fathers) made up the evaluation sample and was 
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representative of the community since the allergy clinic has a diverse population of patients and 
providers (including Caucasian, Vietnamese, Chinese, Korean, Thai, Indian, and Filipino).  
The average age of the children represented in the retrospective chart review was 10 
(youngest at 4, and oldest at 16), with 9 males and 6 females. The clinic providers completed an 
OIT eligibility criteria form for recommendation to entering the program. The inclusion criteria 
for entry into OIT included children with 2 of the 3 positive test results: 1. positive serum 
peanut-specific IgE within the past 18 months, 2. positive skin prick test, 3. positive allergic 
reaction experience before entering the program. Five (30%) of the subjects had a lifetime 
history of at least one anaphylactic event requiring epinephrine. The average peanut-specific IgE 
was 48.6, (minimum 1.34, and max >100). Subjects were allowed to continue any asthma or 
eczema therapies during OIT provided that they were stabilized before starting therapy.  
Criteria for inclusion for this program evaluation included all parents of children 
participating in OIT therapy at the private allergy clinic. Exclusion criteria included parents that 
chose not to provide informed consent or did not participate in the survey. All parents that were 
enrolled in the clinic’s peanut OIT program volunteered to participate in the program survey 
during the second half of their child’s desensitization program (after 20 weeks of starting OIT). 
No parents declined taking the survey and all gave consent for retrospective chart review for 
their children. Receiving honest parental survey answers were important to this evaluation, thus 
parents were informed that the surveys would be kept anonymous and was ensured by instructing 
parents to omit names from the survey, and by giving plain white envelopes for the parents to 
seal the completed survey in. The OIT nurse then placed the blank, sealed envelopes into a large 
legal file folder for storage until analysis.   
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Study Oversight 
 The study protocol, survey, and consent forms first received approval letters from the 
Clinic Director, followed by approval by the Project Chair, committee members, and the 
California State University’s Fresno Institutional Review Board. Two written informed consents 
were obtained from the parents of the subjects enrolled in the program evaluation. The first  
consent provided permission to use the parental survey results in this doctoral project, and the 
second provided a retrospective chart review for collecting adverse event  and OIT success rates 
of each subject.  
Measures 
 The OIT pilot study evaluation follows the CDC’s Appendix F utilizing the Individual 
Evaluation Plan Outline (CDC, 2018), and identifies process improvement elements the 
stakeholders will address before making decisions about expanding the current program. Since 
much of the evaluation outline involves protected information including names of stakeholders, 
and budgetary information, only applicable information will be reported deemed useful by 
readers of this study. In order to continue as a viable program, questions involving program 
success rates, safety outcomes, necessary 
resources, and long term goals were addressed (see Table 1) using what is known from the pilot 
study using fifteen patients over a 10 month retrospective time span.  
All quantifiable outcomes were measured by means of descriptive statistics using data 
collected from chart audits in a retrospective fashion from the pilot study sample with no 
controls. Measures of frequency and central tendencies were used for calculating the total 
number of doses versus the number of reported mild, medium, and severe adverse reactions. 
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These safety measures were then compared to the data reported by published studies from 
respected research institutes where considerably more rigor and larger sample sizes were used.   
Table 1 
 Evaluation Questions & Criteria 
Evaluation Question Criteria or Indicator 
Standards 
(What Constitutes 
“Success”?) 
 
1.How effectiveness is  OIT 
therapy compared to published 
studies? 
 
Number of subjects 
completing OIT program 
vs dropping out. 
>79% success (number of 
patient reaching maintenance 
(Wasserman, et al., 2014) 
2. How common are adverse 
reactions during escalation phase 
of OIT? 
 
% of reported symptoms:  
 
Mild 
Mild/moderate: occurring in 
< 95% of escalations 
 (per results reported by Bird 
et al., 2018) 
 
Moderate 
 
 
Severe: 
< 0.7per 1000 doses 
(per results from Wasserman 
et al., 2014) 
3. Is the allergy clinic addressing 
anxiety reducing practices for 
families with food allergies? 
Parent survey: rating 
anxiety reducing elements 
of OIT program  
 
Parent survey ratings average 
“strongly agree/ agree”. 
4.  Do parents feel the OIT 
information and education they 
are receiving help reduce their 
anxiety about the program? 
 
Parent survey  
Questions  
1, 2, 3, 4,  
 
Parent survey ratings average 
“strongly agree/agree”.  
5. Cost Effectiveness NP vs DR visits for OIT N/A – Program evaluators 
will determine 
6. What pros/cons are parents 
reporting about  OIT? 
Parent survey open-
ended question responses 
Review of answers will direct 
stakeholder decisions about 
OIT program.  
(Taken from CDC’s Appendix F:  Program Evaluation Form) 
 Measures involve patient caregivers’ anxiety with OIT therapy, included a ten-question 
survey listing anxiety-reducing elements the providers considered useful for any OIT program. 
DocuSign Envelope ID: FA0BAE8F-FCA7-4EA1-9BEF-C24143F5C43C
 20 
The parents were asked to give a Likert Scale rating of how helpful each element of their OIT 
experience was in decreasing their anxiety (5=most helpful, 1=least helpful).  The survey was 
given to each child’s parent during the second half of their OIT therapy (during weeks 16-26) 
and took place during the months of September 2018 through February 2019. Before completing 
the survey, the parents signed a consent form that explained confidentiality and anonymity of the 
completed questionnaires.  
Procedure for Data Collection 
Precautions taken to minimize risks included confidentiality and anonymity of parental 
evaluations; the survey was administered by the OIT nurse, no names of patient, parent, or 
associated provider were on the survey and the completed survey were placed in blank individual 
envelopes that the parent could seal upon completion. To insure 100% return of surveys, parents 
were given the survey during their child’s up-dosing appointment, where they had 60 minutes to 
complete the survey. The anonymous surveys were stored in a locked file that only the OIT nurse 
researcher had access to at the private allergy clinic. Once the program evaluation was complete, 
all questionnaires were destroyed by professional shredding service. No compensation was 
provided for the parents participating in this project.  
OIT success rates and adverse reaction rates were gathered by the researcher using 
retrospective chart review. The total number of doses per subject were counted as well as the 
total number of mild, moderate, and severe reactions.  
Data Analysis 
 Parental survey answers were given a Likert scale number: “Strongly agree” became a 5, 
“Agree” a 4, “Neither Agree or not” a 3, “Disagree” a 2, and “Strongly disagree” a 1. These 
scores were loaded into an Excel Spreadsheet and mean scores were computed by the researcher.  
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 Safety analysis was also conducted via Excel by calculating the total number of doses 
administered by all 15 of the children, and adding up all the dose related adverse reactions, 
further specifying mild, medium, and severe allergic reactions. Patients are required to keep a 
dosing diary, and to bring them to each up-dosing appointment for further review by the provider 
before increasing to the next dose. The data from these diaries were collected and uploaded for 
data analysis.  
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CHAPTER 4: RESULTS AND FINDINGS 
The pilot study evaluation focuses on three major themes: 
1.  Success and safety of OIT program in a private clinic setting was compared to 
established research center data, using previously published results by Wasserman, et al. 
(2014 & 2019), and Bird, et al. (2018).  
2. Parental food allergy anxiety was examined by parental survey.  
3. Evaluation of logistical requirements within OIT program generated recommendations 
for process improvements or modifications to the current program, (which will be further 
discussed in the final chapter of this paper). 
Demographic and Study Analysis 
Theme 1: 
Of the 17 parents in the evaluation study sample, discontinued within the first three 
appointments due to their children reporting adverse symptoms. One patient took a six month 
leave due to abdominal pain and vomiting and followed up with a GI specialist (no endoscopy 
was done, but a proton-pump inhibitor was prescribed). The second individual complained of 
“difficulty swallowing” that did not improve with antihistamines, steroids, nor ENT and GI 
follow up. Since his symptoms continued six months after withdrawal from OIT, the providers 
suspected OIT was not the cause of his symptoms. The remaining analysis included the 15 
parents with children that achieved maintenance therapy or reached at least 20 or more weeks of 
therapy. Of the 15 patients all but 2 reached 300 mg by the time the data was collected, resulting 
in an 87% success rate of reaching maintenance, (the remaining two are anticipating to reach 
maintenance within 5 escalations).  
The peanut OIT data of 15 patients between the ages of 4 and 16 (mean 10) was collected 
via retrospective chart review at a time when all had either reached maintenance or were within 5 
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up-dose appointments to maintenance (See Table-2). A total of 2826 doses were administered 
between May 2018 until February 2019, with 12 (80%) of the subjects complained of adverse 
symptoms during OIT escalations, and 3 (20%) had no symptoms at all. The peanut-specific IgE 
for the three subjects without symptoms ranged from 3.85 to >100, suggesting that IgE levels 
have no bearing on the number of adverse symptoms expected.  
 “Mild” symptoms were defined by this project as transient symptoms that resolved within 
30 minutes without the use of antihistamines, such as stomach ache, mouth tingling, mild skin 
pruritis/urticaria. “Moderate” symptoms included any symptom that warranted antihistamines for 
resolution of symptoms such as abdominal pain lasting greater than 30 min or multiple areas of 
urticaria. “Severe” symptoms were classified as any symptom warranting the use of epinephrine 
injectable for resolution.  Four of the patients (27%) started reporting moderate symptoms 
regularly and were prescribed either a daily antihistamine and/or H2 blocker, thus improving 
symptoms for the remainder of the therapy. Mild symptoms were reported by 8 patients, a total 
of 80 times (3%), and moderate symptoms were reported by 4 of the patients 102 times (4%). It 
is also noted that 4 of the 15 patients reported >10 adverse events versus the remaining 11 
patients reported <10 or no symptoms throughout their escalation period (phase 2 of OIT). 
Two anaphylactic events (0.07%) were reported by two patients (once by each) both 
occurred toward the end of the escalation period of therapy. One injection of epinephrine was 
reported to have immediately stopped the reactions of epidermal erythema, chest tightness, and 
difficulty with swallowing, no IV fluids were warranted during the emergency room follow up. 
In both cases, parents reported that the patients did not follow the 2-hour rest protocol. 
Fortunately, both patients reached maintenance and have reported no further adverse symptoms 
with OIT.    
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Table 2 
Sample Analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theme 2: 
Parents were asked to complete the peanut OIT program evaluation survey as part of this 
report in order to assess what elements of the OIT experience were found to be most valuable in 
decreasing their food allergy-related anxiety (See Table 3 for survey questions).  All 15 parents 
of the program sample agreed to complete the survey (chart of responses in Appendix B), 
achieving 100% return. This was accomplished by requesting survey completion during the 
patient’s escalation visit observance time of 60 minutes post up-dosing.  The ten questions 
           Total number (%)__________ 
Sample Size  of study 15* 
No of patients achieving 
Maintenance  13 (87%)    
                
Maintenance target dose 300 mg 
 
Mean Age:  10  (4-16) 
 Female:  6 
 Male:  9 
 
Mean PS-IgE:  48.6 (1.35->100) 
 
Pts without Rxns:  3   (20%) 
Pts with Rxns:  12  (80%) 
 
Total Doses:  2826 
Total # Reactions  184  (7.1%) 
Mild   80  (3%) 
 Moderate  102  (4%) 
 Severe   2  (0.07%)  or  (0.7/1000) 
 
Average weeks on OIT 30 (26 - 34)** 
 
*2 subjects temporarily stopped OIT due to adverse symptoms  
- One has recently restarted OIT (premedicated with daily H2 
blocker) 
- Second subject continues to describe “dysphagia” 6 months 
after OIT stopped.  
** One outlier took 43 weeks to reach maintenance  
           Total number (%)__________ 
Sample Size  of study 15* 
No of patients achieving 
Maintenance  13 (87%)    
                
Maintenance target dose 300 mg 
 
Mean Age:  10  (4-16) 
 Female:  6 
 Male:  9 
 
Mean PS-IgE:  48.6 (1.35->100) 
 
Pts without Rxns:  3   (20%) 
Pts with Rxns:  12  (80%) 
 
Total Doses:  2826 
Total # Reactions  184  (7.1%) 
Mild   80  (3%) 
 Moderate  102  (4%) 
 Severe   2  (0.07%)  or  (0.7/1000) 
 
Average weeks on OIT 30 (26 - 34)** 
 
*2 subjects temporarily stopped OIT due to adverse symptoms  
- One has recently restarted OIT (premedicated with daily H2 
blocker) 
- Second subject continues to describe “dysphagia” 6 months 
after OIT stopped.  
** One outlier took 43 weeks to reach maintenance  
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measured activities that helped ease a parents anxiety about the food allergy program. The 
answers were assigned a Likert scale value in order to calculate mean scores for each question 
(Strongly Agree = 5, Agree = 4, Neither Agree or Disagree = 3, Disagree = 2, and Strongly 
Disagree = 1).  
Table 3  
Parental Survey Questions 
 
 
 
 
 
 
 
 
 
 The results of the survey were compiled in Appendix A with the following scores: The 
parental survey conveyed that education provided by their allergist is considered very helpful 
(score mean=4.7) in easing parental anxiety. Attending an hour long orientation meeting 
discussing how OIT works and the commitment that is involved also scored high in reducing 
parental anxiety (mean =4.8). The parent’s take-home orientation folder explaining OIT, 
timelines, how to treat adverse symptoms, and contact information also received high scores in 
easing anxiety (mean=4.7). The first phase of OIT includes the initial escalation day that takes 
approximately 5 hours and involves a series of very small doses increasing in peanut amount 
spaced 30 minutes apart referred to as oral challenges (OC). After the OC is completed, the OIT 
1. Discussing peanut OIT with my child’s allergy provider helped ease my anxiety 
about the program 
2. The OIT orientation meeting helped ease my anxiety about the program. 
3. The orientation folder was helpful and easy to use 
4. Education provided on the first day of OIT helped ease my anxiety about dosing 
at home. 
5. Knowing I could speak to a provider 24/7 helped ease my anxiety about the 
program. 
6. Knowing I could speak to a psychologist about my child’s food allergies was 
helpful. 
7. Completing my own OIT research helped ease my anxiety about the program 
8. Having quiet activities available during escalation appointments was helpful. 
9. Being involved in an on-line food allergy website/blog has helped ease my 
anxiety about food allergy desensitization. 
10. Speaking to friends about their experiences with peanut desensitization helped 
ease my anxiety about OIT. 
DocuSign Envelope ID: FA0BAE8F-FCA7-4EA1-9BEF-C24143F5C43C
 26 
providers have the opportunity to educate the patients and parents in more detail about how to 
treat a variety of symptoms at home (allergic versus viral illness, etc). Patients and parents are 
also encouraged to practice using the epinephrine injectables as part of the education provided. 
Completing this education scored high among the parents in easing anxiety, resulting in a 4.7 
rating. Having an allergist provider available to speak to the parents 24 hours a day, 7 days a 
week also rated high with a mean score of 4.7 in easing parental anxiety. Since food allergy 
anxiety can be serious,  allergist that have a relationship with psychologists specializing in food 
allergy anxiety could be seen as beneficial, and was a priority for the pilot study providers. None 
of the parents or subjects in this program evaluation warranted or requested referral to 
counseling, but having the option available proved value in decreasing parental anxiety with a 
rating of 4.3. Having quiet diversional activities available during the lengthy appointments were 
also rated 4.1 in easing anxiety, however most families brought their own activities and 
electronic devices for entertainment. Parents today are more apt to initiate their own research 
about food allergies and OIT, and those that did or spoke to friends about OIT rated these 
exercises 4.3 and 4.1 respectively in easing anxiety.  Interestingly enough, online searches and 
blogging on food allergy websites only scored an average of 3.5 in easing parental food allergy 
anxiety. A chart of these responses is found in Appendix B. 
Summary of the Evaluation Results 
 Indicators of success were decided upon in collaboration with the clinic stakeholders and 
the program evaluation author, and is summarized in Table 4: 
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Table 4:  Evaluation Questions & Criteria 
Evaluation Question 
Criteria or 
Indicator 
Standards 
(What Constitutes 
“Success”?) 
Program 
Evaluation  
Results 
 
1.How effectiveness is  
OIT therapy compared to 
published studies? 
 
Number of subjects 
completing OIT 
program vs 
dropping out. 
>79% success (number 
of patient reaching 
maintenance 
(Wasserman, et al., 
2019) 
 
87% of patients 
achieved 
maintenance. 
2. How common are 
adverse reactions (AR) 
during escalation phase of 
OIT? 
 
% of reported 
symptoms:  
 
Mild 
Mild/moderate: 
occurring in < 95% of 
escalations 
 (per results reported 
by Bird et al., 2018) 
Total number of 
patients reporting 
AR:  80% 
 
3% (8 patients) 
 
Moderate 
  
4% (4 patients) 
 
Severe: 
< 0.7per 1000 doses 
(per results from 
Wasserman et al., 
2014) 
 
0.7 in 1000 doses 
(2 patients) 
3. Is the allergy clinic 
addressing anxiety 
reducing practices for 
families with food 
allergies? 
Parent survey: 
rating anxiety 
reducing elements 
of OIT program  
 
Parent survey ratings 
average “strongly 
agree/ agree”. 
 
4.6/5.0  
Mean score 
4.  Do parents feel the 
OIT information and 
education they are 
receiving help reduce 
their anxiety about the 
program? 
 
Parent survey  
Questions  
1, 2, 3, 4,  
 
Parent survey ratings 
average “strongly 
agree/agree”.  
 
Yes (mean score 
of 4.7/5.0) 
5. Cost Effectiveness NP vs DR visits for 
OIT 
N/A – Program 
evaluators will decide 
 
6. What pros/cons are 
parents reporting about  
OIT? 
Parent survey 
open-ended 
question responses 
Review of answers will 
direct stakeholder 
decisions about OIT 
program.  
Parents report: 
“this is a life 
changer for our 
family!  
(See notes for 
complete set of 
responses) 
(Taken from CDC’s Appendix F:  Program Evaluation Form) 
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Evaluation Questions and Criteria Results: 
Evaluation Question 1: Pilot Study OIT program success rate of achieving maintenance 
dosing is equal to published results as measured by the number of subjects completing OIT 
program versus dropping out. The 2014 study by Wasserman et al., was the first to publish 
adverse events during peanut OIT using 5 private practice clinics (see details in literature 
review), and reported 80% of participants reaching maintenance, In comparison, this pilot study 
was able to report 87% of patients reaching maintenance (13 out of 15) by the time data was 
collected, (with the two remaining patients within 5 escalation doses of reaching maintenance).   
Evaluation Question 2: The number of patients experiencing adverse reactions (AR) 
during escalation dosing  is similar to the 95% reported by Bird et al., (2018) as measured by 
twelve of the 15 patients reported AR during the escalation period thus 80% of  the patients 
reported “mild” to “moderate” symptoms. The number of adverse reactions requiring 
epinephrine occurred in 2 separate dose related episodes (out of a total of 2826 doses), resulting 
in 0.7 per 1000 doses. The 2014 study by Wasserman et al., published adverse events requiring 
epinephrine occurred 57 time during 79,726 escalation doses, also resulting in 0.7 per 1000.  
Evaluation Question 3: Parental survey scores rated high for the food allergy anxiety 
reducing elements that were implemented prior to the start of the pilot study, generating scores 
averaging 4.6/5.0.   
Evaluation Question 4: Parents reported the OIT information and education they are 
receiving helped reduce their anxiety about the program with a mean score of 4.7/5.0 
Evaluation Question 5: Cost effectiveness was not reported here, due to limiting 
reportable financial data, but reportable elements will be discussed in Chapter 5.  
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Evaluation Question 6:  Additional comments given by the parents in an open-ended 
question at the end of the survey read:  “Please offer any further suggestions on how to decrease 
anxiety during the desensitization program” 
Response #1:  “Put the allergy clinic phone number on the front of the Orientation Folder for 
quick reference” 
Response #2:  “Being able to schedule appointments on dependably regular basis and having 
appointments start and finish on time are immensely helpful” 
Response #3:  “Nothing can truly prepare nor alleviate the anxiety that comes with watching 
your child eat the very thing that can cause them extreme harm for the first time.  However, the 
reassurance from the staff went a long way in quelling that fear enough to proceed with the 
program. The FNP an RN staff are all truly special people – whom we are grateful for each and 
every day!  After that initial appointment, the anxiety has continued to diminish and now have no 
fear as we continue escalation appointments. I feel confident in this program! Thank you!” 
Response #4: “If the other moms going through at same time were open to a group email/text, 
that may have been added bonus – even just one other mom, not that they weren’t – just a 
suggestion.  A bonus would be a one-page laminate or some type of chart that we could hang up 
in the kitchen:  
1 Calm 
2 dose with food 
3 swish 
4 Calm” 
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CHAPTER 5: DISCUSSION 
Despite several limitations to this paper, analysis of the quantitative data resembled the 
data published from larger more rigorous studies, as noted in Chapter 4. The program evaluation 
template provided formal talking points about the logistics of implementing a new peanut OIT 
program, and were addressed with the OIT staff and stakeholders. Key points will be discussed 
in this final chapter.  
Survey Bias 
 The evaluation sample of parents that was used for this study was one of convenience, 
and represented a skewed gender population with 12 mothers and 3 fathers. A nonresponse bias 
occurred with three of the surveys that had no response to questions that the parents reported as 
“non-applicable” (N/A) but were addressed specifically to non-OIT program elements (such as 
conducting outside research about OIT), and these N/A responses were not calculated into the 
survey mean results. A voluntary response bias may result since parents may have strong 
opinions about their children having the opportunity to be desensitized to peanuts.  The 
researcher attempted to reduce response bias by keeping the surveys anonymous as described in 
chapter 4.  
Limitations 
 The sample size of this pilot study is limited, with 15 parents and 15 children.  An 
attempt to compare data from the 15 patients (children) with larger, more rigorous studies gave 
promising results for the overall program evaluation outcomes. Since this program evaluation 
used a sample of convenience, no blind or control groups were applied. Parental roles (mothers 
versus fathers) may have led to survey response bias, and in the future, surveying both parents 
would be recommended. Adverse reaction reporting in the daily dose diaries may have also been 
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biased since most of the reported symptoms were subjective, such as abdominal pain, or itchy 
mouth. These reactions may have also been under or over reported as well, depending on 
parent’s perception of severity. Another limitation may be that the sample came from a 
geographically non-diverse group of  parents living in the Silicon Valley. 
Program Evaluation Results 
 The following discussion will cover key points the evaluation noted  including program 
modifications that may be warranted. This discussion may be viewed as useful information for 
allergy providers contemplating implementation of a peanut OIT program. 
Staff Education and Competencies 
 During pre-implementation of the peanut OIT program, the champion nurses, nurse 
practitioners, and doctors created protocols for how the initial escalation day will proceed, 
including safety requirements and equipment. Templates were created for nursing and providers 
for easy documentation. The same was created for the up-dosing appointments. Once the 
protocols were agreed upon by the stakeholders, competency checklists were created and all OIT 
providers were signed off on standard procedures required for OIT appointments and handling 
anaphylaxis. OIT nurses are also responsible for fielding calls from parents with children 
undergoing OIT during office hours thus protocol-driven vignettes are used by nurses to refer to 
for the advice line. The NPs are responsible for auditing these calls and following up with any 
concerning questions.  
 Administrative duties such as insurance billing, scheduling OIT appointments, and 
collecting payments were assigned to one person in order to ensure smooth processes. After re-
evaluation of this facet, it appeared that the duties would be better served by two administrators, 
in order to have better coverage when one is out. It was decided that training more administrators 
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did not make sense since following a few weeks of trialing this option resulted in too many 
miscommunications and dropped call backs for scheduling, causing frustration for the families 
involved.  
Parental Education is Key 
Parents appreciate the time spent teaching them about their child’s food allergies.  The 
key point of providing an orientation hour with the parents before starting a peanut OIT program 
is to teach them about how OIT works, how their child may react, and how the provider will help 
them manage the next 6 months. It is crucial that parents understand the daily commitment 
involved, and the protocols that are required for their child’s safety. Having all this information 
provided in an informational guide book allows the parent to go home and process the 
information before making the commitment. The pilot study found that approximately 25% of 
the families that attended orientation decided that they were either not ready or postpone starting 
OIT until they had more time (such as summer months). As a result however, 100% of families 
that enrolled into the program were fully committed, followed the protocols carefully, and were 
either on their way or graduated successfully from the program. While providers discuss OIT as 
an optional therapy with their patients, it is important to include the risks and benefits of OIT for 
clear understanding of the therapy, thus providers need to stay current with food allergy research 
since breakthrough studies continue to be published.  
Program safety discussions with the families have been found to be the cornerstone to the 
success of this program, and were valued by parents with high survey ratings. The best 
opportunity for this occurs once the final oral challenge is complete on day-1 of initial escalation. 
During this time the patient remains in the office for additional observational time, providing 
time for more detailed education to occur for parents. This information covers how to treat mild, 
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moderate, severe symptoms (including epinephrine injectable demonstration and practice), what 
to do if the child is sick with viral illness, travels to higher elevations, or misses a dose. All this 
information is documented and kept in the patient’s personal OIT diary for further reference, 
thus empowering the parents with their own detailed information. Having this individualized 
education period at the end of the first day works well since the anxiety levels tend to decrease 
once the escalation dosing is complete,  and parents are more focused on the education that is 
being provided. 
Allergist Clinic Providing OIT 
Privately managed (non-academic, and “for profit”) institutions are beginning to offer 
OIT services (i.e., Latitudefoodallergycare.com), and are providing allergy desensitization for a 
variety of foods. However, parents that prefer working with their own trusted allergist cannot be 
underestimated.  Parents are looking for a quality of life improvement with OIT, yet they fear 
harm will come to their child. Therapy being provided by an allergist they have developed a 
relationship with while being treated for various environmental allergies, asthma, immunology 
disorders, and/or food allergy management, gives the entrusted allergist an advantage when 
adding peanut OIT to their services.  Since increasing the patient’s peanut tolerance occurs in a 
safe clinic environment, parents can rest assure that emergency treatment can be provided 
immediately if needed. When a parent has a question about their child’s OIT therapy, (especially 
one that warrants immediate attention), providing 24/7 on-call provider coverage is also 
invaluable. The pilot study clinic where this evaluation was done has eleven providers (MDs and 
NPs) that take call without sharing the service with outside providers. This way all calls are 
personalized within the group, and immediate call back can be provided. Interestingly enough, 
OIT parents rarely called for assistance during the pilot study, speculating they were provided 
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with a guide in their orientation book that empowers parents and patients to take care of 
minor/moderate/severe allergic reactions themselves. Secure electronic mail was also found to be 
a convenient means of communication when parents had less timely information they need to 
discuss (such as scheduling conflicts, upcoming travel plans, etc.).  
Cost effective practices 
 This pilot study evaluation considered nurse practitioner led OIT programs that are 
overseen by physicians as a cost effective practice, provided these NPs are comfortable with 
conducting oral challenges and handling anaphylaxis. NPs are well practiced in educating 
patients and families, recognizing and treating the signs and symptoms of allergic reactions, 
prescribing treatments and medications (such as epinephrine injectors), and ordering initial 
diagnostic tests for potential patients. This evaluation also found that having one provider 
overseeing the OIT program (i.e., lead nurse practitioner) allowed for better management of the 
program and flow of communications with doctors, nurses, and administrators, thus not 
interfering with the daily appointment schedules and prescribed therapies of physicians.  
Creating a guideline that specifies the eligibility criteria for potential OIT patients was 
considered cost effective by this pilot study since it ruled out candidates with contraindications to 
OIT. In order to create a comprehensive eligibility criteria guideline, Box 8 (general 
contraindications to FA desensitization) in the report published by Panjo, et al., (2017) was 
utilized. The one-page criteria form that was developed allowed prescribing physicians to check 
off the appropriate criteria that must be met in order for the patient to be eligible for peanut OIT.  
This eligibility form was then given to the OIT lead NP to evaluate followed by initiating 
an OIT orientation meeting for the patient and family. This orientation meeting included the OIT 
administrator which conducted the Q&A of the financial aspects of the program, including 
DocuSign Envelope ID: FA0BAE8F-FCA7-4EA1-9BEF-C24143F5C43C
 35 
individualized discussions about insurance coverage for each family. By taking the time to orient 
the patient and family to the program, the OIT champions felt less time was spent with multiple 
phone calls for clarifications about the program, and dropout rates would most likely be 
minimized by explaining the program in detail before starting OIT.  
Based on this pilot study evaluation, other staffing recommendations depend on the size 
of the practice but should include at least one to two nurses and NPs that specialize in OIT. 
Continuity of care greatly reduces parental anxiety during therapy because the parents learn to 
trust these caregivers as they do their allergist. In order to reduce miscommunication and 
scheduling conflicts, it is also recommended that one (or two) administrators champion the 
scheduling of OIT patients and handles the insurance claims. This administrator helps keep 
schedules running smoothly and handles all the non-medical aspects of running the program.  
It is important to set aside a “nut free” space that can be used only for OIT allowing 
multiple children to be observed by one nurse during up dosing appointments. This pilot study 
found that 4 children per nurse were the limit in terms of safety and space available in the clinic.  
Since the children are required to be observed for approximately 45-60 minutes (Wasserman, et 
al., 2019), separating the OIT patients allows for uninterrupted provider visits in the rest of the 
clinic. When clinic space is limited, OIT programs can be scheduled during the afternoons of less 
busy days, or even a few evenings a week to optimize office space.  This pilot study found most 
parents preferred afternoon up-dosing appointments as well as Saturday appointments due to 
work and school commitments.  
Offering Extra Social Support 
 Having a working relationship with a licensed psychologist specializing in food allergy 
anxiety can also be beneficial when referring any parents requiring more specialized counseling.  
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A few parents that had children up-dosing at the same time were able to connect and create their 
own “parent support group” where they were able to discuss various topics while their children 
were being observed after up-dosing. Creating an environment which facilitates this type of 
community within the clinic would benefit many parents and children. The pilot study found it 
useful to have quiet diversional activities available  to keep children motivated to stay calm 
while enjoying time with their parents and other children attending therapy. These activities 
included age appropriate books, coloring pages and crayons, playing cards for games, origami 
crafts, and board games.  
Conclusions 
 Peanut OIT is recognized as an optional therapy that decreases the incidence of 
anaphylaxis due to accidental peanut ingestion (Shreffler, et al., 2018). Peanut OIT has also 
shown to improve QOL for peanut allergic individuals and their families (Epstein-Rigbi et al., 
2019). With careful review of this program evaluation via a pilot study, it appears that OIT 
therapy that takes place in non-institutional settings can be as successful as conventional research 
environments. However, further research using larger sample sizes is warranted and currently 
being collected by the Food Allergy Support Team (FAST), (Wasserman, Jones, & Windom, 
2018). The survey results of this program evaluation points to key strategies for minimizing food 
allergy related anxiety for parents. These strategies include developing and implementing 
educational programs within OIT to help prepare patients and their families with knowledge 
about the process and what to expect during therapy, and how to treat allergy related symptoms, 
including anaphylaxis. An effective means of communications between providers and patients is 
also encouraged since provider availability is seen as an anxiety-reducing element of therapy by 
this evaluation.  
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 Allergy care providers eagerly anticipate evidence-based practice guidelines to be 
published once FDA approves the new peanut immunotherapy pharmaceutical products. This is 
the first pilot study program evaluation that takes into consideration parental anxiety reducing 
elements as well as logistical aspects of implementing a peanut OIT program. Providers 
interested in providing a similar program may find helpful suggestions in this doctoral project. 
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Appendix A: Parental Survey and Results (means of responses) 
 
Peanut OIT Program Evaluation 
 
Strongly 
Agree 
     (5) 
 
Agree 
(4) 
Neither 
Agree or 
Disagree 
      (3) 
 
Disagree 
     (2) 
Strongly 
Disagree 
     (1) 
1. Discussing peanut OIT with my child’s 
allergy provider helped ease my anxiety 
about the program 
 
       
         4.7  
 
 
 
 
 
Range     
5-4 
 
 
 
 
 
 
2. The OIT orientation meeting helped 
ease my anxiety about the program. 
 
4.8 
 
 
 
 
 
Range 
5-4 
 
 
 
 
 
 
 
3. The orientation folder was helpful and 
easy to use 
 
       4.7 
 
 
 
 
 
Range 
5-4 
 
 
 
 
 
 
 
4. Education provided on the first day of 
OIT helped ease my anxiety about dosing 
at home. 
 
        4.7 
           
 
 
 
 
Range 
5-4 
 
 
 
 
 
 
 
5. Knowing I could speak to a provider 
24/7 helped ease my anxiety about the 
program. 
 
        4.7     
 
 
 
 
Range 
5-3 
 
 
 
 
 
 
 
6. Knowing I could speak to a 
psychologist about my child’s food 
allergies was helpful. 
 
 
 
 
 
 4.3 
               
 
Range 
5-3 
 
 
 
 
 
 
 
7. Completing my own OIT research 
helped ease my anxiety about the 
program 
 
 
 
 
4.3 
              
 
Range 
5-3 
 
 
 
 
 
 
 
8. Having quiet activities available during 
escalation appointments was helpful. 
 
 
 
 
 
4.1 
               
 
Range 
5-3 
 
 
 
 
 
 
 
9. Being involved in an on-line food 
allergy website/blog has helped ease my 
anxiety about food allergy desensitization 
 
                 
3.5  Range   
5-3 
  
10. Speaking to friends about their 
experiences with peanut desensitization 
helped ease my anxiety about OIT. 
 
4.1 
     
Range 
5-3 
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Appendix B:  Parent Survey Results 
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